Last reviewed · How we verify
NCT05639569
Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study
trial testing Ankura™ TAA Stent Graft System in Aneurysm Thoracic in 145 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Lifetech Scientific (Shenzhen) Co., Ltd. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 145 |
| Start date | 3 May 2023 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2030 |
| Sites | 8 locations across Italy, Russia, Greece, Germany |
Drugs / interventions tested
- Ankura™ TAA Stent Graft System
Conditions studied
- Aneurysm Thoracic — all drugs for Aneurysm Thoracic →
- Dissection of Thoracic Aorta — all drugs for Dissection of Thoracic Aorta →
Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd. — full company profile →
Who can join
Adults 18 to 85, any sex, with Aneurysm Thoracic or Dissection of Thoracic Aorta. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect clinical data on patient outcomes, evaluate the safety and performance of Ankura TAA Stent Graft System and Surpass Super Stiff Guidewire, and build clinical evidence for patients with Descending Thoracic Aneurysm (DTA) or Type B Aortic Dissection (TBAD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05639569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Lifetech Scientific (Shenzhen) Co., Ltd. trials
Trials by the same sponsor.
- NCT07385599 — FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients · NA · active not recruiting
- NCT06915545 — Study on the Aortic Arch Single Branch Stent Graft System · NA · recruiting
- NCT06849635 — Cera™ ASD Occluder Post-Market Clinical Follow-Up Study · recruiting
- NCT06700174 — Lifetech AcuMark™ Sizing Balloon Post-Market Clinical Follow-up Study · recruiting
- NCT06520774 — Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05639569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lifetech Scientific (Shenzhen) Co., Ltd.
- Last refreshed: 22 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05639569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing